Mario Cuervo
Psychiatry · Miami, FLNPI 1578664363
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,036 of the $6,962 with a category attached, or 86.7%. It is spread thinly across 20 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,649 and has fallen 53.2% since, to $1,238 in 2025.
Across 263 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$827
- Teva Pharmaceuticals USA, Inc.$758
- Johnson & Johnson$536
- Alkermes, Inc.$444
- plus $1K from 14 others
Across 334 payments — averaging $20,111 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$4.8M
- Bioxcel Therapeutics, Inc.$440K
- Sage Therapeutics, LLC$436K
- Axsome Therapeutics, Inc.$321K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$254K
- Avanir Pharmaceuticals, Inc.$150K
- plus $308K from 3 others
What the payments were for
- Travel & lodging$81412%
- Food & beverage$6,03687%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 2 | $1,479 |
| AbbVie | 77 | $1,446 |
| Otsuka America Pharmaceutical, Inc. | 38 | $827 |
| Teva Pharmaceuticals USA, Inc. | 38 | $758 |
| Johnson & Johnson | 28 | $536 |
| Alkermes, Inc. | 19 | $444 |
| E.r. Squibb & Sons, L.L.C. | 9 | $320 |
| Indivior Inc. | 9 | $224 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $205 |
| Axsome Therapeutics, Inc. | 7 | $191 |
| Lundbeck LLC | 8 | $159 |
| Neurocrine Biosciences, Inc. | 5 | $89 |
| Ironshore Pharmaceuticals Inc. | 4 | $68 |
| Almatica Pharma LLC | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Viiv Healthcare Company | 1 | $29 |
| Tempus AI, Inc | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $24 |
| Braeburn Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,479
- LYBALVI$447
- VRAYLAR$125
- COBENFY$124
How this compares
$6,962 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 15 | $19,812 |
| Quetiapine Fumarate | 250 | $3,985 |
| Aripiprazole | 47 | $3,583 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 27 | $1,745 |
| Trazodone Hcl | 218 | $1,634 |
| Buspirone Hcl | 172 | $1,196 |
| Clonazepam | 156 | $1,165 |
| Mirtazapine | 100 | $810 |
| Duloxetine Hcl | 43 | $800 |
| Memantine Hcl | 41 | $770 |
| Alprazolam | 149 | $770 |
| Paroxetine Hcl | 52 | $664 |
| Hydroxyzine Pamoate | 44 | $562 |
| Gabapentin | 44 | $547 |
| Escitalopram Oxalate | 103 | $530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $827 | $19,81215 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $406103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.